echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Hematol Oncol: Efficacy of selinexor in the treatment of relapsed/refractory diffuse large B lymphocyte tumors: SADAL study

    J Hematol Oncol: Efficacy of selinexor in the treatment of relapsed/refractory diffuse large B lymphocyte tumors: SADAL study

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Relapsed/refractory diffuse large B-lymphocyte tumors (RR DLBCL) have limited options after ≥2 lines of treatment progress, and the expected overall survival (OS) is <6 months
    .


    The SADAL study evaluated the efficacy of single-agent selinexor (selinexor) in the treatment of RR DLBCL.


    Relapsed/refractory diffuse large B-lymphocyte tumors (RR DLBCL) have limited options after ≥2 lines of treatment progress, and the expected overall survival (OS) is <6 months


    The median age was 67 years, and 44.
    8% of patients were ≥70 years old
    .


    At a median follow-up of 14.


    The median age was 67 years, and 44.


    Subgroup survival comparison

    Subgroup survival comparison

    The median OS of patients with or without autologous stem cell transplantation (ASCT) was 10.
    9 months and 7.
    8 months, respectively (HR 1.
    39 (0.
    85, 2.
    28), p = 0.
    185)
    .


    Among patients receiving current systemic treatment, the median OS of patients who reached CR or PR was significantly prolonged (11.


    The median OS of patients with or without autologous stem cell transplantation (ASCT) was 10.


    Impact of previous treatment on survival

    Impact of previous treatment on survival

    The study observed that one patient with an expected survival of less than 6 months achieved a median survival of 9 months after using selinexor
    .


    It was also observed that 4 patients had not achieved CR in previous treatments, and achieved CR or PR after using selinexor


    The study observed that one patient with an expected survival of less than 6 months achieved a median survival of 9 months after using selinexor


    In summary, selinexor can obtain survival benefits in the treatment of relapsed/refractory diffuse large B lymphocyte tumors, regardless of age, previous ASCT treatment and refractory status


    Original source:

    Maerevoet M, Zijlstra JM, Follows G, et al.


    Maerevoet M, Zijlstra JM, Follows G, et al.
    Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
    J Hematol Oncol.
    2021 Jul 16;14(1):111.
    doi: 10.
    1186/s13045-021-01122-1.
    PMID: 34271963; PMCID: PMC8283921.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.